- Home
- TS vs ROIV Comparison
TS vs ROIV Comparison
Compare TS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TS | ROIV |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Luxembourg | United Kingdom |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 20.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TS | ROIV |
|---|---|---|
| Price | $58.04 | $26.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $48.60 | $27.56 |
| AVG Volume (30 Days) | 2.0M | ★ 4.4M |
| Earning Date | 04-29-2026 | 02-06-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $1.00 | N/A |
| Revenue Next Year | $3.30 | $594.84 |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.06 | $8.73 |
| 52 Week High | $58.69 | $30.33 |
Technical Indicators
Market Signals| Indicator | TS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 71.54 | 42.52 |
| Support Level | $34.25 | $20.46 |
| Resistance Level | N/A | $27.94 |
| Average True Range (ATR) | 1.15 | 0.88 |
| MACD | 0.08 | -0.38 |
| Stochastic Oscillator | 85.11 | 1.04 |
Price Performance
Historical ComparisonAbout TS Tenaris S.A.
Tenaris is one of the largest global producers of oil country tubular goods, which are used primarily in the construction of oil and gas wells. Its production facilities are located primarily in the US, Argentina, Mexico, and Italy. Tenaris' premium OCTG products are among the most trusted by oil companies for use in the most challenging applications, including deep-water offshore wells and horizontal shale wells.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.